Skip to main content Skip to navigation
BV786 Rat Anti-Mouse CD355 (CRTAM)
Product Details
Down Arrow Up Arrow


BD OptiBuild™
class I-restricted T cell-associated molecule; crtam; cytotoxic and regulatory T-cell molecule
Mouse (Tested in Development)
Rat WI, also known as Wistar (outbred) IgG2a, κ
Mouse CRTAM extracellular sequence Recombinant Protein
Flow cytometry (Qualified)
0.2 mg/ml
AB_2874014
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV786 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
  10. Cy is a trademark of GE Healthcare.
749760 Rev. 3
Antibody Details
Down Arrow Up Arrow
11-5

The 11-5 monoclonal antibody specifically recognizes MHC class I-restricted T cell-associated molecule (CRTAM) that is also known as CD355 or Cytotoxic and regulatory T-cell molecule. CD355 (CRTAM) is encoded by Crtam which belongs to the Nectin family of cell adhesion molecules within the immunoglobulin superfamily. This type I transmembrane glycoprotein contains a V-type Ig domain, followed by a C-type Ig domain, a transmembrane region, and an intracellular region that contains a PDZ-binding motif at the C terminus. CD355 (CRTAM) is transiently expressed as a homodimer on activated NK cells, NKT cells, γδ T cells, CD8+ T cells, or CD4+ T cells. Through its V-type Ig domain, CRTAM (CD355) binds to Nectin-like molecule 2 (Necl-2) and plays important roles in adhesive interactions between different cell types and in cellular migration.

The antibody was conjugated to BD Horizon™ BV786 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 786-nm.  BD Horizon BV786 can be excited by the violet laser and detected in a filter used to detect Cy™7-like dyes (eg, 780/60-nm filter).

749760 Rev. 3
Format Details
Down Arrow Up Arrow
BV786
The BD Horizon Brilliant Violet™ 786 (BV786) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an Ex Max of 407-nm and an acceptor dye with an Em Max at 786-nm.  BV786, driven by BD innovation, is designed to be excited by the violet laser and detected using a filter, centered near 785 nm (e.g. 780/60 nm bandpass filter).  Please ensure that your instrument’s configurations (lasers and filters) are appropriate for this dye.
altImg
BV786
Violet 405 nm
407 nm
786 nm
749760 Rev.3
Citations & References
Down Arrow Up Arrow

Development References (5)

  1. Arase N, Takeuchi A, Unno M, et al. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells.. Int Immunol. 2005; 17(9):1227-37. (Immunogen: Flow cytometry). View Reference
  2. Fuchs A, Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol. 2006; 16(5):359-366. (Biology). View Reference
  3. Kennedy J, Vicari AP, Saylor V, et al. A molecular analysis of NKT cells: identification of a class-I restricted T cell-associated molecule (CRTAM).. J Leukoc Biol. 2000; 67(5):725-34. (Biology). View Reference
  4. Takeuchi A, Badr Mel S, Miyauchi K, et al. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J Exp Med. 2016; 213(1):123-38. (Clone-specific: Flow cytometry). View Reference
  5. Takeuchi A, Itoh Y, Takumi A, et al. CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. J Immunol. 2009; 183(7):4220-4228. (Biology). View Reference
View All (5) View Less
749760 Rev. 3

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.